IBRX News & Events

ImmunityBio has secured $75M in non-dilutive financing under its existing Royalty Interest Purchase Agreement with Oberland Capital, increasing the total committed capital under the Agreement to $375M. The amended agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap. Simultaneous with the closing of the amendment to the RIPA, Nant Capital, an entity affiliated with our Executive Chairman, converted $25M principal amount with the issuance of 4.6M shares of the company's common stock to Nant Capital and the reduction of debt under the $505M December 2024 Promissory Note

ImmunityBio announced that based on the Independent Data Monitoring Committee, IDMC, review of the interim data, the committee recommended that the study is adequately powered to detect the pre-specified clinically meaningful difference in complete response rate between the experimental arm and the control arm at the protocol-specified power, in the randomized QUILT-2.005 study. The QUILT-2.005 study was designed to detect the pre-specified difference in CR rate between ANKTIVA plus Bacillus Calmette-Guerin, BCG, and BCG alone in patients with BCG-naive non-muscle invasive bladder cancer, NMIBC, with carcinoma in situ, CIS, with or without papillary disease, based on its review of the planned interim analysis.

ImmunoBio shares fell about 24% after the FDA's Office of Prescription Drug Promotion issued a warning letter regarding promotional communications for ANKTIVA, citing false or misleading claims and inadequate risk disclosure, BTIG tells investors in a research note. The company has 15 days to respond, and the issue is seen as resolvable, with the stock pullback viewed as a potential entry point ahead of 2H26 BCG-naive bladder cancer data, the firm says. BTIG maintains a Buy rating and $13 price target on the shares.